Goblet cell adenocarcinoma of the appendix guide graphic: grades, staging, surgery, and follow-up, from Appendicure

Goblet Cell Adenocarcinoma of the Appendix: Grades, Treatment, and Follow-Up

Goblet cell adenocarcinoma (GCA) is a rare cancer that starts in the appendix. It used to be called goblet cell carcinoid, but it behaves like an adenocarcinoma, not like a carcinoid tumor, and it is treated that way. The 2025 consensus guidelines from the Peritoneal Surface Malignancy (PSM) Consortium recommend a right hemicolectomy for people with goblet cell adenocarcinoma who are healthy enough for it. What happens next depends on the stage and on whether the cancer has reached the lining of the abdomen.

Many people learn they have goblet cell adenocarcinoma (GCA) after an appendectomy for what looked like ordinary appendicitis. The tumor tends to spread along the wall of the appendix instead of forming a clear lump, so it is easy to miss on a scan. Then the pathology report arrives with a long name, a grade, and sometimes an older label like goblet cell carcinoid. We built this page to explain what those words mean and what the current guidelines recommend.

The treatment sections follow the 2025 consensus guidelines from the PSM Consortium. More than 130 specialists, including surgeons, medical oncologists, pathologists, and patient advocates, voted on each step. Dr. Michael Foote, who reviewed this page, is one of the guideline authors. Sources are listed at the bottom.

What goblet cell adenocarcinoma is

Goblet cell adenocarcinoma is made of small tubes and clusters of cells that look like goblet cells, the mucus-making cells that line the gut. Mixed in are other gut-lining cells and, often, cells with hormone-making (neuroendocrine) features. Pathologists call this an amphicrine tumor, meaning it shows both gland-type and hormone-type features at once.

The 2025 guidelines estimate that goblet cell adenocarcinoma makes up about 1 in 5 of the gland-type (epithelial) cancers of the appendix. Low-grade tumors tend to behave less aggressively. Higher-grade tumors lose their tidy tube pattern and can look and act like poorly differentiated adenocarcinoma or signet ring cell carcinoma.

Why the name changed from goblet cell carcinoid

For decades this tumor was called goblet cell carcinoid because, at low grade, it looks bland under the microscope. That name caused real confusion. It suggested a slow neuroendocrine tumor, and it left doctors unsure whether neuroendocrine staging and treatments applied. Over time, pathologists proposed new names and grading systems, including adenocarcinoid, mixed carcinoid-adenocarcinoma, and adenocarcinoma ex-goblet cell carcinoid.

In 2018, a team led by Dr. Masato Yozu showed that these tumors are closer to adenocarcinoma and proposed the name goblet cell adenocarcinoma, with a grading system like the one used for colon cancer. The World Health Organization (WHO) adopted that name and grading in 2019. If your report uses an older name, it is describing the same disease. The post goblet cell adenocarcinoma: what the new name means for patients goes deeper on the history.

Understanding the grade on your report

The WHO grades GCA by how much of the tumor still grows in the low-grade pattern of tubes or small clusters. The less of that pattern there is, the higher the grade.

WHO gradeLow-grade tube or cluster pattern
Grade 1More than 75 percent of the tumor
Grade 250 to 75 percent of the tumor
Grade 3Less than 50 percent of the tumor

Older reports may use the Tang system instead. The 2025 guidelines translate it this way: Tang A (typical goblet cell carcinoid) is roughly grade 1, the signet ring cell type of adenocarcinoma ex-goblet cell carcinoid is grade 1 or 2, and the poorly differentiated carcinoma type is likely grade 3.

Grade matters for outlook, and higher grades behave more aggressively. Grading is also hard to do consistently. In a 2026 study, seven pathologists with appendix expertise graded the same 20 GCA cases, and all seven agreed on the grade for only 4 of them. The authors concluded that a simpler low-grade versus high-grade system may be more reliable. Our post on why experts disagree on goblet cell adenocarcinoma grade covers that study. It is one more reason the guidelines recommend review of your tissue by an expert pathologist.

Goblet cell adenocarcinoma is staged with the same TNM system used for other appendiceal adenocarcinomas, not the system used for neuroendocrine tumors. The types of appendix cancer page explains each T, N, and M category.

Tests after a goblet cell adenocarcinoma diagnosis

The 2025 guidelines put GCA in the same pathway as other appendiceal adenocarcinomas. The first workup includes:

  • A detailed history and physical exam.
  • Blood tumor markers: CEA, CA-125, and CA 19-9, with CRP considered.
  • Cross-sectional imaging with CT or MRI, if it has not been done.
  • A colonoscopy to look for a separate growth in the colon.
  • Review of the tissue by an expert pathologist and discussion at a multidisciplinary tumor board.
  • Comprehensive tumor profiling (genomic testing of the tumor) to look for possible drug targets. Germline testing for inherited cancer risk may be considered, especially with a family history of cancer.

The guidelines also recommend checking for support needs, including support groups, social work, financial help, emotional support, and fertility counseling.

Treatment for goblet cell adenocarcinoma under the 2025 guidelines

When the cancer has not spread to the abdomen

The guidelines recommend a right hemicolectomy, which removes the right side of the colon along with nearby lymph nodes. The target is at least 12 lymph nodes, the same standard used in colon cancer. For most appendiceal adenocarcinomas, the guidelines allow one exception: a well differentiated mucinous adenocarcinoma fully confined to the appendix. They make no exception for GCA. The PSM Consortium recommends right hemicolectomy for it without exception.

Not every expert group agrees. The Peritoneal Surface Oncology Group International (PSOGI) suggests a right hemicolectomy may not be needed for the lowest-grade GCA (WHO grade 1 or Tang A) that is confined to the appendix with no high-risk features. If you are in that situation, it is reasonable to ask your surgeon how they weigh the two views.

Chemotherapy after surgery

After surgery, the final stage guides the next step:

  • Stage III (cancer in at least one lymph node), or stage II with high-risk features: the guidelines say to consider chemotherapy after surgery. The usual options are FOLFOX, or a stronger three-drug regimen such as FOLFOXIRI or FOLFIRINOX, which causes more side effects. Treatment usually lasts 3 to 6 months, with a goal of 6.
  • Stage I or II without high-risk features: the guidelines recommend surveillance, because there is not enough evidence that chemotherapy helps.

The high-risk features confirmed in appendix cancer studies are lymph node involvement, signet ring cells, and less differentiated or nonmucinous tumors. The guidelines do not recommend chemotherapy before surgery when the cancer has not spread, because it would delay the operation.

When goblet cell adenocarcinoma has spread to the abdomen

Goblet cell adenocarcinoma most often spreads to the peritoneum, the lining of the abdomen. Part 2 of the 2025 guidelines covers this situation. It recommends right hemicolectomy, and cytoreductive surgery (CRS) if any peritoneal disease is present. CRS is a long operation to remove all visible tumor in the abdomen, often paired with heated chemotherapy inside the abdomen (HIPEC). The guidelines recommend giving chemotherapy through the vein before CRS when possible, then checking the response before planning surgery. If someone has surgery first, they should get a full course of chemotherapy afterward.

Spread from GCA is not the same as pseudomyxoma peritonei (PMP). The guidelines list it with nonmucinous adenocarcinoma as peritoneal metastases, separate from the mucinous disease that causes PMP. The difference matters, because the two follow different treatment paths. The grade of the tumor in the abdomen also matters. A 2020 study of 63 patients who had CRS with HIPEC found that WHO grade 3 disease in the abdomen predicted a worse outlook.

Evidence on chemotherapy for advanced GCA is still limited. A 2026 study of 210 patients treated at one UK peritoneal center found that chemotherapy was linked with benefit for people with high-grade disease, positive lymph nodes, or tumor left behind after surgery. It was a look back at past records, not a randomized trial, so it cannot prove cause and effect. Surgery for spread to the abdomen belongs at a center with real experience. The medical centers and providers page lists centers that treat appendix cancer often.

Surveillance after goblet cell adenocarcinoma

Follow-up for GCA is more frequent than for low-grade mucinous tumors. The 2025 guidelines recommend:

  • A visit with a history and physical exam.
  • CT or MRI. Either is acceptable, and the guidelines suggest staying with one.
  • A CEA blood test, plus any other marker that was high at any point.
  • A schedule of every 3 to 6 months for 2 to 4 years, then once a year until 5 to 10 years after treatment.

Scans can miss early spread to the abdominal lining, so a second-look laparoscopy may be considered when there is concern. The guidelines also say circulating tumor DNA (ctDNA) blood tests can be considered during follow-up, especially for high-grade or signet ring cell disease, while noting that the evidence in appendix cancer is limited.

The genetics of goblet cell adenocarcinoma

The 2025 guidelines note clear differences in the gene changes found in GCA compared with mucinous appendix tumors. That is one more reason GCA should not be treated as if it were the same disease as PMP. The guidelines recommend genomic testing of the tumor for anyone whose cancer has spread, preferably on tissue rather than blood. Studies that link these gene changes to which treatments work are still small. Pooling data from many patients is how that changes, and it is a large part of why the Appendicure registry exists.

Add your goblet cell data to the registry

The Appendicure Patient-Led Global Appendix Cancer Registry collects pathology, genomic, and molecular data from people with every appendiceal cancer type, including goblet cell. It is IRB-reviewed, free, and open worldwide. Please use the form for where you live.

Already enrolled? Add new reports or correct your record.

Frequently asked questions about goblet cell adenocarcinoma

Is goblet cell adenocarcinoma a carcinoid or neuroendocrine tumor?

No. It was called goblet cell carcinoid for many years, but the World Health Organization renamed it goblet cell adenocarcinoma in 2019 because it behaves like an adenocarcinoma. It is staged and treated as an appendiceal adenocarcinoma, not as a neuroendocrine tumor.

Do I need a right hemicolectomy for goblet cell adenocarcinoma?

The 2025 PSM Consortium guidelines recommend right hemicolectomy with removal of nearby lymph nodes for goblet cell adenocarcinoma without exception, for people healthy enough for surgery. The international PSOGI group suggests it may not be needed for the lowest-grade tumors confined to the appendix.

Is goblet cell adenocarcinoma the same as PMP?

No. When goblet cell adenocarcinoma spreads to the abdomen, the 2025 guidelines treat it as peritoneal metastases, in the same group as nonmucinous adenocarcinoma. Pseudomyxoma peritonei (PMP) comes from mucinous tumors and follows a different treatment path.

What do the grades of goblet cell adenocarcinoma mean?

The WHO grades it by how much of the tumor keeps a low-grade tube or cluster pattern: grade 1 is more than 75 percent, grade 2 is 50 to 75 percent, and grade 3 is less than 50 percent. Higher grades behave more aggressively.

Do I need chemotherapy for goblet cell adenocarcinoma?

It depends on stage. The 2025 guidelines say to consider chemotherapy after surgery for stage III disease or stage II with high-risk features, and to give chemotherapy before cytoreductive surgery when the cancer has spread to the abdomen. Stage I or II without high-risk features is followed with surveillance.

How long is follow-up after goblet cell adenocarcinoma?

The 2025 guidelines recommend imaging, a CEA blood test, and an exam every 3 to 6 months for 2 to 4 years, then once a year until 5 to 10 years after treatment.

Sources

  • Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement. Cancer. 2025;131(13):e35867. doi.org/10.1002/cncr.35867
  • Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement. Cancer. 2025;131(13):e35874. doi.org/10.1002/cncr.35874
  • Yozu M, Johncilla ME, Srivastava A, et al. Histologic and outcome study supports reclassifying appendiceal goblet cell carcinoids as goblet cell adenocarcinomas, and grading and staging similarly to colonic adenocarcinomas. Am J Surg Pathol. 2018;42(7):898-910. doi.org/10.1097/PAS.0000000000001056
  • Marins LV, Murden R, Misdraji J, et al. High interobserver variability exists in grading appendiceal goblet cell adenocarcinoma using World Health Organization 5th edition criteria. Histopathology. 2026;89(4):658-669. doi.org/10.1111/his.70205
  • Shyu S, Choudry H, Hall L, et al. Clinicopathological analysis of appendiceal goblet cell adenocarcinoma with peritoneal metastasis: World Health Organization grade predicts survival following cytoreductive surgery with intraperitoneal chemotherapy. Histopathology. 2020;77(5):798-809. doi.org/10.1111/his.14189
  • Strach MC, Aziz O, Nonaka D, et al. Long-term outcomes, pathological classification and prognostic factors in localised and advanced appendiceal goblet cell adenocarcinoma following cytoreductive surgery, intraperitoneal and systemic chemotherapy. ESMO Open. 2026;11(7):108245. doi.org/10.1016/j.esmoop.2026.108245

Medically reviewed by Michael Foote, MD, Medical Oncologist & Physician-Scientist, Memorial Sloan Kettering. This page was written with AI assistance. It is for education and does not replace advice from your own care team. Last updated November 2026.